Several large-scale human studies, including SUSTAIN-6 for semaglutide and LEADER for liraglutide, have found no significant increase in the risk of MTC or other thyroid cancers compared to placebo groups
The clinical trial programme for semaglutide 2.4 mg (STEP trials), which included over 4,500 participants followed for up to 68 weeks as documented in the European Public Assessment Report (EPAR), did not identify diverticulitis as a treatment-emergent adverse event occurring at rates higher than placebo
At 24 h post-transfection with GST plasmids, cells were treated with AFB 1 at the concentration of IC 30 for 24 h
Two sets of four dilutions, each of CS-g-P, CS-g-P/B-GHS, and FLZ loaded CS-g-P/B-GHScarrier(50 g/ml), were prepared in sterile Mc Cartney bottles
NuScience offers a focused catalog of approximately 10 products, which suggests more concentrated quality control compared to vendors selling dozens or hundreds of compounds
Short-term studies of CJC-1295 with DAC reported no serious adverse reactions, but the data are limited